Amplia Enters Into Preclinical Collaboration With Korean Specialist Drug Screening Company Next and Bio

Release Highlights:

• A preclinical research collaboration with specialist drug screening company Next & Bio has been established.
• The collaboration explores the effect of Amplia’s FAK inhibitors in combination with experimental drugs called kRas inhibitors.
• kRas inhibitors are being developed for the treatment of pancreatic cancer.